Announced details
Curative treatment of dystrophic epidermolysis bullosa; treatment of inherited intractable diseases
The Company has been conducting research and development into “regeneration-inducing medicines” together with Osaka University. The patent applicant is Osaka University, a national university corporation.
Application number: 10-2021-7025601; registration number: To be determined; application region: South Korea
There will be no impact on full-year results for the fiscal year ending July 2026. Any material matter requiring disclosure will be disclosed promptly.
The company does not address Contract Value / Offering price.
Japan Agency for Medical Research and Development (AMED)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Stem cell gene therapy technology (Development Code: SR-GT1) / Therapeutic product for dystrophic epidermolysis bullosa |
| Counterparty | Osaka University National University Corporation |
| Relationship with the Company | The Company has been conducting research and development into “regeneration-inducing medicines” together with Osaka University. The patent applicant is Osaka University, a national university corporation. |
| Applicable area | Curative treatment of dystrophic epidermolysis bullosa; treatment of inherited intractable diseases |
| Registration number and expiry date | Application number: 10-2021-7025601; registration number: To be determined; application region: South Korea |
| Impact on Business Performance | There will be no impact on full-year results for the fiscal year ending July 2026. Any material matter requiring disclosure will be disclosed promptly. |
| Source | Japan Agency for Medical Research and Development (AMED) |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company aims to achieve a curative treatment for dystrophic epidermolysis bullosa and establish curative treatments in combination with its other proprietary technologies.